Combretastatin A1 phosphate Oxi4503; CA1P; Combretastatin A1 diphosphate|cas:288847-35-8|西域试剂

Combretastatin A1 phosphate Oxi4503; CA1P; Combretastatin A1 diphosphate,98.00%

产品编号：Bellancom-16147| CAS NO：288847-35-8| 分子式：C₁₈H₂₂O₁₂P₂| 分子量：492.31

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-16147	￥6900.00	杭州北京（现货）
Bellancom-16147	￥11050.00	杭州北京（现货）
Bellancom-16147	￥23200.00	杭州北京（现货）
Bellancom-16147	￥37000.00	杭州北京（现货）
Bellancom-16147	￥59200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Combretastatin A1 phosphate Oxi4503; CA1P; Combretastatin A1 diphosphate

产品介绍

Combretastatin A1 phosphate (Oxi4503; CA1P; Combretastatin A1 diphosphate) 是一种有效的血管破坏剂。Combretastatin A1 phosphate 对肿瘤具有抗血管生成作用。Combretastatin A1 phosphate 具有用于胰腺神经内分泌肿瘤研究的潜力。

生物活性

Combretastatin A1 phosphate (Oxi4503; CA1P; Combretastatin A1 diphosphate) is a potent vascular disruptive agent. Combretastatin A1 phosphate exerts anti-angiogenic effects on tumors. Combretastatin A1 phosphate has the potential for the research of pancreatic neuroendocrine tumors.

体外研究

体内研究

Combretastatin A1 phosphate (100 mg/kg; I.p.; once at day 16 post tumor induction) 显示出抗肿瘤活性，并对小鼠肿瘤发挥抗血管生成作用当与 Sunitinib (HY-10255A) 连用时。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male CBA mice (CRC liver metastasis)
Dosage:	100 mg/kg (received 40 mg/kg of Sunitinib daily from day 14 to 21 post tumor induction)
Administration:	I.p.; once at day 16 post tumor induction
Result:	Demonstrated a significantly decreased mean liver weight compared to livers from non tumor bearing animals, significantly reduced tumor vessels.

体内研究

Combretastatin A1 phosphate (100 mg/kg; I.p.; once at day 16 post tumor induction) 显示出抗肿瘤活性，并对小鼠肿瘤发挥抗血管生成作用当与 Sunitinib (HY-10255A) 连用时。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male CBA mice (CRC liver metastasis)
Dosage:	100 mg/kg (received 40 mg/kg of Sunitinib daily from day 14 to 21 post tumor induction)
Administration:	I.p.; once at day 16 post tumor induction
Result:	Demonstrated a significantly decreased mean liver weight compared to livers from non tumor bearing animals, significantly reduced tumor vessels.